StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.40−0.41 (-7.06%)

Close on Nov 17, 2026Market cap $413.20MP/E –Yield –

Candel Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Candel Therapeutics's ebitda for the twelve months ending Jun 30, 2023 was -$35.39M. For fiscal 2022 it was -$33.94M.

Annual ebitda

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$33.94M–
FY2021Dec 31, 2021-$25.49M–
FY2020Dec 31, 2020-$13.72M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023-$9.38M–
Q1 FY2023Mar 31, 2023-$9.40M–
Q4 FY2022Dec 31, 2022-$7.92M–
Q3 FY2022Sep 30, 2022-$8.68M–
Q2 FY2022Jun 30, 2022-$8.55M–
Q1 FY2022Mar 31, 2022-$8.82M–
Q4 FY2021Dec 31, 2021-$7.56M–
Q3 FY2021Sep 30, 2021-$8.01M–
Q2 FY2021Jun 30, 2021-$5.29M–
Q1 FY2021Mar 31, 2021-$4.63M–
Q4 FY2020Dec 31, 2020-$6.12M–
Q3 FY2020Sep 30, 2020-$2.71M–
Q2 FY2020Jun 30, 2020-$2.60M–

More Candel Therapeutics figures

See a number that looks wrong?